{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:56:58Z","timestamp":1794747418860,"version":"4.9.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kyowa Kirin Co., Ltd."}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Pegfilgrastim, a long-acting form of granulocyte-colony stimulating factor, with a convenient single-injection dosage, is being investigated for peripheral blood stem cell (PBSC) mobilization in healthy volunteers. However, data on the adequate dose of pegfilgrastim for PBSC mobilization are limited. This phase 2, single-arm study evaluated the efficacy and safety of pegfilgrastim for PBSC mobilization in healthy volunteers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>The study comprised 2 phases: pilot (steps 1\u20133, dose escalation, a single subcutaneous dose of 3.6, 7.2, and 10.8\u2009mg pegfilgrastim, respectively) and evaluation (step 4, efficacy and safety assessments). The primary endpoint was the proportion of subjects who achieved mobilization of \u226520\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/L cluster of differentiation 34 positive (CD34<jats:sup>+<\/jats:sup>) cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Thirty-five subjects (6 each in steps 1 and 2 and 23 in step 4) were included. In the pilot phase, step 3 with a 10.8\u2009mg dose was not conducted due to favorable outcomes in step 2 (desired CD34<jats:sup>+<\/jats:sup> cell count), at 7.2\u2009mg pegfilgrastim, which was identified as the optimal dose for the evaluation phase. In the evaluation phase, successful CD34<jats:sup>+<\/jats:sup> mobilization was achieved in all 23 subjects. The mean peripheral blood CD34<jats:sup>+<\/jats:sup> cells count peaked on day 5. Back pain, thrombocytopenia, transient elevations of alkaline phosphatase, and lactate dehydrogenase were the most common adverse events. All adverse events were mild, and none led to study discontinuation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>A single-dose pegfilgrastim successfully mobilized an optimal number of CD34<jats:sup>+<\/jats:sup> cells and was well tolerated. Pegfilgrastim could be an alternative option for PBSC mobilization in healthy volunteers. The trial was registered at www.clinicaltrials.gov (NCT03993639).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004880","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T05:00:27Z","timestamp":1701147627000},"page":"996-1003","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Single-dose Pegfilgrastim for CD34+ Cell Mobilization in Healthy Volunteers: A Phase 2 Study"],"prefix":"10.1097","volume":"108","author":[{"given":"Hideki","family":"Goto","sequence":"first","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan."},{"name":"Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sugita","sequence":"additional","affiliation":[{"name":"Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hayasaka","sequence":"additional","affiliation":[{"name":"Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Sunagoya","sequence":"additional","affiliation":[{"name":"Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Hatase","sequence":"additional","affiliation":[{"name":"Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsumi","family":"Nishida","sequence":"additional","affiliation":[{"name":"Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ichihashi","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co Ltd, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Odera","sequence":"additional","affiliation":[{"name":"Kyowa Kirin Co Ltd, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Senjo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Ara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souichi","family":"Shiratori","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[{"name":"Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan."},{"name":"Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,23]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.blre.2018.11.001","article-title":"Allogeneic hematopoietic cell transplantation; the current renaissance.","volume":"34","author":"Copelan","year":"2019","journal-title":"Blood Rev"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/blood.V97.9.2541","article-title":"Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation.","volume":"97","author":"Rowley","year":"2001","journal-title":"Blood"},{"key":"R4-20250604","first-page":"3702","article-title":"Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation.","volume":"95","author":"Richard","year":"2000","journal-title":"Blood"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"100771","DOI":"10.1016\/j.blre.2020.100771","article-title":"Getting blood out of a stone: identification and management of patients with poor hematopoietic cell mobilization.","volume":"47","author":"Chen","year":"2021","journal-title":"Blood Rev"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.seminhematol.2019.11.003","article-title":"Mobilization and collection of cells in the hematologic compartment for cellular therapies: stem cell collection with G-CSF\/plerixafor, collecting lymphocytes\/monocytes.","volume":"56","author":"Elizabeth","year":"2019","journal-title":"Semin Hematol"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","article-title":"Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.","volume":"20","author":"Duong","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of pegfilgrastim.","volume":"50","author":"Yang","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jjco\/hyp038","article-title":"A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.","volume":"39","author":"Yamamoto","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/jca.21816","article-title":"Feasibility and efficacy of low-dose pegfilgrastim for CD34+ cell mobilization in lymphoma.","volume":"35","author":"Goto","year":"2020","journal-title":"J Clin Apher"},{"key":"R11-20250604","first-page":"1665","article-title":"Single-dose pegfilgrastim for the mobilization of allogeneic CD34+peripheral blood progenitor cells in healthy family and unrelated donors.","volume":"90","author":"Kroschinsky","year":"2005","journal-title":"Haematologica"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.bbmt.2006.03.001","article-title":"Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.","volume":"12","author":"Hill","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12185-014-1507-0","article-title":"Successful peripheral blood stem cell mobilization using pegfilgrastim in allogeneic stem cell transplantation.","volume":"99","author":"Chanswangphuwana","year":"2014","journal-title":"Int J Hematol"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/0091270006288731","article-title":"Pharmacokinetic\/pharmacodynamic modeling of pegfilgrastim in healthy subjects.","volume":"46","author":"Roskos","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilization in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1537-2995.2003.00361.x","article-title":"Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim.","volume":"43","author":"Moncada","year":"2003","journal-title":"Transfusion"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1537-2995.2009.02546.x","article-title":"Preharvest hematopoietic progenitor cell counts predict CD34+ cell yields in granulocyte-colony-stimulating factor-mobilized peripheral blood stem cell harvest in healthy donors.","volume":"50","author":"Sang","year":"2010","journal-title":"Transfusion"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"Proposed definition of \u2018poor mobilizer\u2019 in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group poItaliano Trapianto di Midollo Osseo.","volume":"47","author":"Olivieri","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1537-2995.2004.03078.x","article-title":"Peripheral blood circulating immature cell counts predict CD34+ cell yields in G-CSF-induced PBPC mobilization in healthy donors.","volume":"44","author":"Kozuka","year":"2004","journal-title":"Transfusion"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation.","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1007\/s00520-015-2654-4","article-title":"Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.","volume":"23","author":"Masuda","year":"2015","journal-title":"Support Care Cancer"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jca.20082","article-title":"Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (GCSF).","volume":"21","author":"Martino","year":"2006","journal-title":"J Clin Apher"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1046\/j.1537-2995.2002.00010.x","article-title":"Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors.","volume":"42","author":"De La Rubia","year":"2002","journal-title":"Transfusion"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0301-472X(99)00112-5","article-title":"A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans.","volume":"27","author":"Molineux","year":"1999","journal-title":"Exp Hematol"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3389\/fonc.2020.01598","article-title":"Is it better to mobilize hematopoietic stem cells with pegfilgrastim in healthy donors during allogeneic hematopoietic stem cell transplantation?","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:11:59Z","timestamp":1749060719000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,23]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004880","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,23]]}}}